SCHEMBL2279675

SCHEMBL2279675

Cc1cc(O)c(C(=O)C=Cc2ccc(OCC#N)cc2)c(=O)[nH]1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.52
HTT P42858 4/20 0.52
SMN1; SMN2 Q16637 4/20 0.52
NPSR1 Q6W5P4 2/20 0.52
SLC5A1 P13866 5/20 0.51
SLC5A2 P31639 5/20 0.51
NPC1 O15118 1/20 0.50
PKM P14618 1/20 0.50
RAB9A P51151 1/20 0.50
PADI4 Q9UM07 2/20 0.48
BCHE P06276 1/20 0.44
ACHE P22303 1/20 0.44
MAPT P10636 2/20 0.44
CYSLTR1 Q9Y271 2/20 0.43
ABCG2 Q9UNQ0 1/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
KDM4E B2RXH2 1/20 0.43
ALDH1A1 P00352 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2279670 1.00 LMNA (0.52) LMNAHTTSMN1; SMN2NPSR1SLC5A1
SCHEMBL2279949 0.89 ABCG2 (0.46) LMNAHTTSMN1; SMN2NPSR1PADI4
SCHEMBL2279952 0.89 ABCG2 (0.46) LMNAHTTSMN1; SMN2NPSR1PADI4
SCHEMBL2284568 0.85 LMNA (0.54) LMNAHTTSMN1; SMN2NPSR1SLC5A1
SCHEMBL2284564 0.85 LMNA (0.54) LMNAHTTSMN1; SMN2NPSR1SLC5A1
SCHEMBL12374656 0.84 LMNA (0.53) LMNAHTTSMN1; SMN2NPSR1SLC5A1
SCHEMBL2279822 0.83 LMNA (0.52) LMNAHTTSMN1; SMN2NPSR1SLC5A1
SCHEMBL2279826 0.83 LMNA (0.52) LMNAHTTSMN1; SMN2NPSR1SLC5A1
SCHEMBL2282156 0.78 PADI4 (0.66) LMNAHTTNPC1RAB9APADI4
SCHEMBL2282160 0.78 PADI4 (0.66) LMNAHTTNPC1RAB9APADI4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7989478-B2 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-08-02 US disclosed
US-20060211680-A1 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2006-09-21 US disclosed
EP-1671948-A1 CINNAMOYL COMPOUND AND USE OF THE SAME Sumitomo Chemical Company, Limited (JP) 2006-06-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060211680-A1 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis COL2A1, COL1A1, COL14A1 LMNA 537/4885HTT 4798/4885SMN1; SMN2 3766/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.